Filing Flows › PTC Therapeutics (PTCT) › Q3 2026 › vs Q2 2026
PTC Therapeutics (PTCT) Q3 2026 vs Q2 2026 (quarter over quarter)
PTC Therapeutics's revenue fell $2.7M (-0.8%) from $361M in Q2 2026 to $358M in Q3 2026. The biggest changes: Collaboration and license revenue −$50.4M (-100%); Net product revenue +$37.1M (+16%); Royalty revenue +$10.6M (+15%).
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Sephience | $182M | $151M | $30.6M | +20% |
| Translarna | $48.5M | $42.2M | $6.3M | +15% |
| Emflaza | $25.1M | $24.6M | $460K | +2% |
| Upstaza/Kebilidi | $14.6M | $11.2M | $3.4M | +30% |
| All other products | $5.9M | $9.5M | −$3.6M | -38% |
| Net product revenue | $276M | $239M | $37.1M | +16% |
| Royalty revenue | $81.7M | $71.1M | $10.6M | +15% |
| Collaboration and license revenue | $229K | $50.6M | −$50.4M | -100% |
| Revenue | $358M | $361M | −$2.7M | -0.8% |
| Net loss | $51.7M | −$83.5M | $135M | — |
| Costs & expenses | $410M | $361M | $49.0M | +14% |
| Operating costs | $333M | $212M | $121M | +57% |
| Interest & other, net | $66.2M | $51.4M | $14.8M | +29% |
| Income tax | $10.6M | $14.0M | −$3.4M | -25% |
| Research & development | $105M | $99.2M | $6.2M | +6% |
| SG&A | $80.1M | $80.6M | −$549K | -0.7% |
| Other operating costs | $147M | $31.8M | $115M | +364% |
| Operating cash sources | $66.0M | −$89.9M | $156M | — |
| Depreciation & amortization | $16.8M | $15.9M | $943K | +6% |
| Share-based compensation | $23.8M | $23.3M | $536K | +2% |
| Cash used in operations | $25.3M | −$129M | $154M | — |
| Net loss absorbed | $51.7M | −$83.5M | $135M | — |
| Working capital & other | $14.3M | −$6.5M | $20.7M | — |
Questions
How much did PTC Therapeutics's revenue grow quarter over quarter in Q3 2026?
PTC Therapeutics's revenue fell $2.7M (-0.8%) from $361M in Q2 2026 to $358M in Q3 2026.
What drove PTC Therapeutics's revenue change in Q3 2026?
Collaboration and license revenue −$50.4M (-100%); Net product revenue +$37.1M (+16%); Royalty revenue +$10.6M (+15%).